No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Asset Management - Global
This trust's primary objective is to mirror the U.S. dollar valuation of the Singapore Dollar. It provides both institutional and individual investors with an accessible and economical method to gain financial exposure equivalent to directly holding the Singapore currency. Furthermore, the transaction expenses incurred when buying these shares are not anticipated to surpass the typical costs associated with acquiring other publicly traded stocks.
No one on the platform currently holds FXSG.
No tracked institution reports a position in FXSG as of their last filing.
No one on the platform has traded FXSG yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Analyst estimates unavailable for this ticker.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| FXSGInvesco CurrencyShares Singapore Dollar Trust | $70.23 | -0.22% | $3M | — |
| BUDXCannabis Growth ETF | $9.97 | -2.59% | $4M | — |
| EMGDSimplify Emerging Markets Equity PLUS Downside Convexity ETF | $16.70 | +0.29% | $4M | — |
| FHKFirst Trust Hong Kong AlphaDEX Fund | $34.58 | -0.79% | $3M | — |
| FXCHInvesco CurrencyShares Chinese Renminbi Trust | $69.69 | -0.08% | $3M | — |
| MSUSLHA Market State Tactical U.S. Equity ETF | $22.91 | -0.13% | $3M | — |
| PRVTTema Listed Private Managers ETF | $23.36 | -0.47% | $4M | — |
Source: Financial Modeling Prep · peers by sector/industry
The investment seeks to reflect the price in USD of the Singapore Dollar. The Shares are intended to provide institutional and retail investors with a simple, cost-effective means of gaining investment benefits similar to those of holding Singapore Dollars. The costs of purchasing shares should not exceed the costs associated with purchasing any other publicly-traded equity securities.
No constituent disclosure available for this fund yet.